RoosterBio Inc
We believe the talented team at Sartorius is uniquely suited to provide our mutual customers with scalable hMSC systems to expedite their cell-based therapeutic programs. - Margot Connor, CEO of RoosterBio
FREDERICK, Md. (PRWEB) December 02, 2020
RoosterBio, Inc, a leading supplier of innovative cellular therapy bioprocess tools and scalable manufacturing solutions for regenerative medicine, today announced it entered into an exclusive agency agreement with Sartorius Korea Biotech, a subsidiary of the Sartorius Group, a leading international partner of the biopharmaceutical and life science research sectors. This strategic partnership combines Sartorius’ proven expertise in providing high-caliber bioprocess testing, technical and customer services to the local South Korean market, as well as its global reach, and RoosterBio’s advanced platform of RUO and cGMP-grade human mesenchymal stem/stromal cell (hMSC) working cell banks, optimized paired media, and hMSC bioprocess systems. This winning combination sets the stage for accelerating the development of new, effective medical treatments and expands RoosterBio’s footprint into Asia, especially in South Korea.
“South Korea is a preeminent innovator in hMSCs, and the South Korean biotech ecosystem has been flourishing according to every measure of growth. One of the first MSC therapies was developed in Korea, clearing an entirely new path to treat previously incurable diseases,” said RoosterBio CEO Margot Connor. “We are delighted to be working with Sartorius Korea Biotech in our global effort to industrialize the supply chain for next-gen treatments, and we are committed to accelerating the commercialization of cell- and gene-based therapies. We believe the talented team at Sartorius is uniquely suited to provide our mutual customers with scalable hMSC systems to expedite their cell-based therapeutic programs.”
Under the terms of the agreement, Sartorius Korea Biotech will engage with its customers as an exclusive agent for RoosterBio to facilitate sales operations and increase the market potential for RoosterBio products on an exclusive basis in South Korea.
“RoosterBio’s commercialized product systems standardize hMSC manufacturing to remove years of time and millions of dollars from the timeline of traditional mesenchymal cell therapeutic product development and clinical translation efforts,” said Duck Sang Kim, Managing Director of Sartorius Korea Biotech. “We look forward to introducing this synergistic biotechnology relationship to South Korea.”
About RoosterBio, Inc
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field. Visit http://www.roosterbio.com.
About Sartorius Korea Biotech, Ltd.
Sartorius Korea Biotech based in Pangyo, South Korea, addresses the evolving needs of the biomanufacturing industry to produce biotech medications and vaccines safely and efficiently. The company is a subsidiary of the Sartorius Group, a leading international partner of life science research and the biopharmaceutical industry, and offers a diversified business portfolio reflecting the products and services of the two Group divisions, Bioprocess Solutions and Lab Products & Services. Sartorius Korea Biotech provides pharmaceutical and laboratory equipment, validation service, training, engineering and consulting, and KOLAS calibration, among other products and services. Visit http://www.sartorius.com